Xarelto approved!

What a tool! Gee to think you will find similar warnings in the PI of every other anticoagulant. Let's see how things settle out at the end of the year, only then could someone make serious predictions.
Now go back into your hole you came from!

 

For all you wondering, pradaxa does NOT carry this warning! There was NO muscle spasms or "leakage". JNJ does a sneaky shady study ( I.e., a per protocol study design) I won't vet my life on a drug this serious.

 

Thanks for clarifying the labeling and the story behind the study "dax-man", your compassion for patients and dedication to all that is honest in pharma is overwhelming!

 

Technical expertise needed to develop new products is lost long time ago.
Nowadays could not even license in.
Xarelto, bapineuzumab, Natrecor ( Scios) and it will keep going…
Bozos at the wheel.

 

The global market for these oral warfarin alternatives is expected to grow to $20 billion. Pradaxa has the first-to-market advantage, but some analysts believe Xarelto can quickly establish itself as an easier-to-use rival that may also carry fewer side effects. Xarelto is a once-a-day drug, whereas Pradaxa is administered twice daily. But at least in the U.S., Xarelto may not be deemed superior to warfarin, but only "non-inferior" to the older drug. Eliquis could well qualify for a superiority claim, giving it a big advantage over the other two.

"Given that Pradaxa has only just been launched in Europe for atrial fibrillation and does not have the DVT indications, but does have a warning on increased heart attack risk, we believe Xarelto will have a very competitive profile in Europe," Maxwell Craig of UniCredit told the Wall Street Journal. "Eliquis looks to be the key competitor, but will be around 10 months behind Xarelto and will not have the DVT indication at launch."

 

Pfizer and BMS are going to destroy Xarelto.

 

Who knows when the FDA is going to respond on Xarelto for A Fib?

 

Supposed to be this Friday. Let's keep our fingers crossed